Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03351101 · ClinicalTrials.gov registry record · NA
Clinical Study of Approved Contact Lenses
A NA study of Myopia, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 271
- Enrollment target
- 11
- Study locations
NCT03351101: Completed NA study of Myopia, sponsored by Bausch & Lomb Incorporated.
NCT03351101 is a NA study of Myopia that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 271 participants, roughly in line with the 265-participant average among 90 other Myopia trials with a reported enrollment target. The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03351101, a NA study of Myopia, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 271 participants
- Enrollment target
- 11
- Study locations
Study Summary
Evaluation of Johnson \& Johnson Acuvue Vita (senofilcon C) soft contact lenses to the Bausch + Lomb Ultra (samfilcon A) soft contact lenses
Primary Outcome
The 100 point , take home questionnaire evaluated performance of the lenses based on subject responses. Possible scores were 0-100. Higher scores indicated greater comfort.
Conditions Studied
Interventions
- DEVICE Senofilcon C
- DEVICE Samfilcon A
Study Locations (11)
Florida
- Valeant Site 06 - Orlando
- Valeant Site 01 - Orlando
- Valeant Site 05 - Sarasota
California
- valeant Site 02 - San Diego
- Valeant Site 03 - San Francisco
Colorado
- Valeant Site 04 - Denver
Kansas
- Valeant Site 07 - Pittsburg
Missouri
- Valeant Site 08 - Warrensburg
New York
- Valeant Site 09 - Vestal
Ohio
- Valeant Site 10 - Powell
Wisconsin
- Valeant Site 11 - New Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2017-10-23 |
| Est. Completion | 2017-12-08 |
| Phase | NA |
What the finished NCT03351101 record still lists
NCT03351101 is an interventional study that assigns participants to a tested intervention. The registered 271 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 265-participant average among 90 other Myopia trials with a reported enrollment target.
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Senofilcon C is the first listed.
NCT03351101 lists 11 locations in 8 states (Florida, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT03351101 about?
NCT03351101 is a clinical study titled "Clinical Study of Approved Contact Lenses". Evaluation of Johnson \& Johnson Acuvue Vita (senofilcon C) soft contact lenses to the Bausch + Lomb Ultra (samfilcon A) soft contact lenses
What is the current status of trial NCT03351101?
This trial is currently completed. It is a NA study. The enrollment target is 271 participants. The study started on 2017-10-23. Estimated completion is 2017-12-08.
What conditions does trial NCT03351101 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT03351101?
The interventions under investigation include: Senofilcon C (DEVICE), Samfilcon A (DEVICE).
Who is sponsoring clinical trial NCT03351101?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03351101 being conducted?
This trial has 11 study locations across California, Colorado, Florida, Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03351101's enrollment target sits among peer trials
271 19th of 90 higher than 72 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03609216 · 271 participants · Phase 2
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI